Iron-Levothyroxine Interaction: Formulation-Specific Effects
The interaction between iron and levothyroxine is formulation-dependent: liquid levothyroxine can be taken simultaneously with oral iron without significant absorption impairment, while tablet levothyroxine requires separation from oral iron; intravenous iron does not interact with any levothyroxine formulation.
The Core Interaction Mechanism
The iron-levothyroxine interaction occurs through chelation in the gastrointestinal tract, which only affects oral iron taken with oral levothyroxine tablets 1. The FDA labeling explicitly states that iron supplements can decrease levothyroxine absorption and recommends not taking levothyroxine tablets within 4 hours of iron 1.
Liquid Levothyroxine: The Game-Changer
Liquid levothyroxine formulations are resistant to iron sequestration and can be taken concomitantly with oral iron salts without absorption impairment 2. This represents a critical clinical advantage:
- A 2017 study demonstrated that switching from tablet to liquid levothyroxine at the same dose in patients with iron-induced malabsorption resulted in TSH normalization (from 7.48 ± 5.8 to 1.95 ± 1.3 mU/L, P < 0.001) 2
- 95% of patients achieved TSH ≤4.12 mU/L with liquid formulation versus only 26% with tablets 2
- The effect was consistent whether patients were taking calcium or iron supplements 2
A 2023 systematic review confirmed that liquid levothyroxine formulations can be ingested with iron salts with no impairment of absorption, while tablet formulations show impaired absorption when taken concomitantly 3.
Real-World Evidence Supports Liquid Formulations
A large population-based study using Italian primary care data (3,965 patients) found that liquid levothyroxine users were less likely to require dose increases during exposure to drug-drug interactions compared to tablet users (IRR = 0.84; 95% CI: 0.77-0.92) 4. This was particularly pronounced in post-surgical hypothyroidism patients (IRR = 0.75) 4.
Intravenous Iron: No Interaction
Intravenous iron does not interact with levothyroxine in any formulation because the chelation mechanism requires gastrointestinal contact 5. A 2026 case report demonstrated rapid TSH normalization (from >100 to 0.42 mU/L within 6 weeks) when oral iron was discontinued and replaced with intravenous iron, despite maintaining the same levothyroxine dose 5.
Critical Caveat: Dose Separation May Not Be Sufficient
Even with appropriate 4-hour separation between tablet levothyroxine and oral iron, clinically significant interactions can persist 5. The 2026 case report documented severe refractory hypothyroidism despite morning levothyroxine and evening iron (>4 hours apart), which only resolved after switching to intravenous iron 5. This challenges the conventional wisdom that separation alone is adequate.
Clinical Algorithm
For patients requiring both levothyroxine and iron:
- First-line approach: Use liquid levothyroxine formulation with oral iron (no separation needed) 2
- Alternative: Use intravenous iron with any levothyroxine formulation 5
- If tablet levothyroxine must be used: Separate by ≥4 hours 1, but monitor closely as this may still be insufficient 5
- Monitor TSH at 6-8 weeks after any change in iron supplementation or formulation 2
Soft-Gel Capsules: Insufficient Evidence
The 2023 review notes that more studies are necessary to confirm whether soft-gel capsule levothyroxine formulations share the same resistance to iron interaction as liquid formulations 3. The 2025 ETA guidelines discuss liquid and softgel formulations together but acknowledge the evidence base is stronger for liquid preparations 6.
Population Impact
A large observational study of nearly 11,000 patients found that iron supplementation increased TSH by 0.22 mU/L (P < 0.001), with 7.5% of patients experiencing a clinically significant TSH increase >5 mU/L 7. This underscores the clinical relevance of this interaction in real-world practice.